SCHEMBL7534767

SCHEMBL7534767

CCCNc1cc(C(F)(F)F)ccc1C=S

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 6/20 0.39
CYP1A2 P05177 3/20 0.39
LMNA P02545 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
ALDH1A1 P00352 2/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
TLR7 Q9NYK1 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953826 0.85 TRPA1 (0.42) TRPA1CYP1A2NPSR1CCNCCDK8
SCHEMBL954777 0.78 TRPA1 (0.45) TRPA1CYP1A2NPSR1ALDH1A1POLB
SCHEMBL954776 0.78 TRPA1 (0.45) TRPA1CYP1A2NPSR1ALDH1A1POLB
SCHEMBL7529379 0.78 TRPA1 (0.43) TRPA1CYP1A2LMNANPSR1ALDH1A1
SCHEMBL19848395 0.76 TRPA1 (0.42) TRPA1CYP1A2LMNANPSR1ALDH1A1
SCHEMBL356817 0.76 LMNA (0.43) TRPA1CYP1A2LMNANPSR1ALDH1A1
SCHEMBL7530542 0.76 NPSR1 (0.55) TRPA1CYP1A2LMNANPSR1ALDH1A1
SCHEMBL953866 0.76 ALDH1A1 (0.43) TRPA1CYP1A2LMNANPSR1ALDH1A1
SCHEMBL953867 0.76 ALDH1A1 (0.43) TRPA1CYP1A2LMNANPSR1ALDH1A1
SCHEMBL14015045 0.76 VDR (0.50) TRPA1CYP1A2LMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them FONTAINE EVELYNE (FR) 2002-09-26 US disclosed
EP-0934290-B1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI SYNTHELABO (FR) 2002-04-17 EP disclosed
US-6344470-B1 Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same SANOFI-SYNTHELABO (FR) 2002-02-05 US disclosed
EP-0934290-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1999-08-11 EP disclosed
WO-1998015543-A1 AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137740-A1 Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them CRHR1, ADRA1D, ADRB1 TRPA1 433/4885CYP1A2 638/4885LMNA 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.